TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02078583
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02078583
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01990677
Drug: 25mg Eplerenone
Normalized name: eplerenone 25 MG
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be given 25mg Eplerenone (or 50mg Eplerenone) or placebo throughout the study and the dosage will be based on the serum potassium/creatine levels. Patients will be randomized 2:1 such that 36 patients in each group will receive eplerenone and 16 patients in each group will receive placebo
Study: NCT01990677
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be given placebo throughout the study from day one, other patients may be tapered down to placebo based on the serum potassium/creatine levels. 16 patients in each group will receive placebo.
Study: NCT00439556
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03507556
Drug: Triple Paste metronidazole, ciprofloxacin and minocycline mixed with sterile glycol
Approvals — FDA: no, EMA: no, PMDA: no
Description: triple paste of metronidazole, ciprofloxacin and minocycline mixed with sterile glycol
Study: NCT00571259
Drug: Heparin 1000U/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis
Study: NCT00571259
Drug: 4% Sodium Citrate with Gentamicin 320 mcg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis
Study: NCT00092508
Drug: Asacol®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00741884
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo BID for 7 weeks
Study: NCT00060996
Drug: Remodulin® (treprostinil sodium) Injection
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03921710
Drug: CAPA-IVM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immature oocytes were plated into a 4-well dish (Nunc, Denmark) at 10 COCs/well using CAPA medium (Medicult IVM medium; Origio, Denmark supplemented with 1 mIU/mL rFSH, 5 ng/mL insulin, 10 nM estradiol, 10 mg/mL human serum albumin \[SAGE, Denmark\] and 25 nM CNP under oil for 24 h at 37°C, 6% carbon dioxide in air). After 24 hours, COCs were washed and transferred into IVM medium (Origio, Denmark) containing 5 ng/mL insulin, 10 nM estradiol, 100 ng/mL human recombinant amphiregulin and 100 mIU/mL rFSH, and incubated under oil for 30 h at 37°C, 6% carbon dioxide in air.
Study: NCT03921710
Drug: Standard-IVM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immature oocytes are plated into a 4-well dish at 10 COCs/well using IVM medium supplemented with 75 mIU/mL recombinant FSH (Merck, Switzerland), 100 mIU/mL hCG (MSD, USA), 0.01 mg/mL growth hormone (Merck, Switzerland) and 10 mg/mL human serum albumin (SAGE, Denmark). COCs were incubated for 30 hours at 37°C, 6% carbon dioxide in air.
Study: NCT00353743
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00353743
Drug: doxycycline plus metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: doxycycline 200mg/day plus metronidazole 500mg/day up to 10 days of treatment (additional to the hospital treatment)
Study: NCT00393679
Drug: artemether-lumefantrine (AL)
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine.
Study: NCT01195805
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet twice a day for 28 days
Study: NCT01195805
Drug: Amiloride
Normalized name: Amiloride
DrugBank: Amiloride (DB00594)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet twice a day for 28 days
Study: NCT02181556
Drug: FOLFIRI Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection of FOLFIRI and Aflibercept every 14 days until progression of disease
Study: NCT03010787
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single and multiple dose
Study: NCT04348513
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same as with T3 solution for injection.
Study: NCT01387321
Drug: BYL719
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00703547
Drug: GSK586529 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK586529 will be provided as white gelatin capsule with a dose of 3 milligrams.
Study: NCT00703547
Drug: GSK586529 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK586529 will be provided as a yellow film-coated tablets for oral administration at three different strengths 10 milligrams, 60 milligrams and 120 milligrams.
Study: NCT00703547
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets and capsules will be provided to subjects.
Study: NCT02084771
Drug: Intravenous Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to this arm will receive intravenous isotonic (0.9%) saline. The rate of isotonic saline will be 3 mL/kg given the one hour before CT and 1 mL/kg/hour for 6 hours post-CT as per Canadian guidelines. Patients weighing more than 110 kg will receive the rate as per a 110 kg patient. The dose will be rounded up to the nearest 5 mL.
Study: NCT03571087
Drug: HL140 5/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1) Treatment(W0\~W8), Extension(W9\~W20): 6Tab./q.d. HL140 5/10(Rosuvastatin5mg/Ezetimibe10mg) : ●♤♡□△◇~●: HL140 5/10mg, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab.5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo
Study: NCT03571087
Drug: HL140 10/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1) Treatment(W0\~W8), Extension(W9\~W20): 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg) : ○♠♡□△◇~○: HL140 5/10mg placebo, ♠: HL140 10/10mg, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo
Study: NCT03571087
Drug: HL140 20/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1) Treatment(W0\~W8), Extension(W9\~W20): 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg) : ○♤♥□△◇~○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♥: HL140 20/10mg, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo
Study: NCT03571087
Drug: Rosuvastatin 5mg → HL140 5/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Treatment(W0\~W8): 6Tab./q.d. Rosuvastatin 5mg : ○♤♡■△◇~   ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo,♡: HL140 20/10mg placebo, ■: Crestor Tab. 5mg, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo~2. Extension period(W9\~W20): 6Tab./q.d. HL1405/10(Rosuvastatin5mg/Ezetimibe10mg) : ●♤♡□△◇~   * HL140 5/10mg, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo
Study: NCT03571087
Drug: Rosuvastatin 10mg → HL140 10/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Treatment(W0\~W8): 6Tab./q.d. Rosuvastatin 10mg : ○♤♡□▲◇~   ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, ▲: Crestor Tab. 10mg, ◇: Crestor Tab. 20mg placebo~2. Extension period(W9\~W20): 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg) : ○♠♡□△◇~   * HL140 5/10mg placebo, ♠: HL140 10/10mg, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo
Study: NCT03571087
Drug: Rosuvastatin 20mg → HL140 20/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Treatment(W0\~W8): 6Tab./q.d.Rosuvastatin 20mg : ○♤♡□△◆~   ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◆: Crestor Tab. 20mg~2. Extension period(W9\~W20): 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg) : ○♤♥□△◇ ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♥: HL140 20/10mg, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo
Study: NCT02693574
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01653522
Drug: Triptan
Normalized name: Oxitriptan
DrugBank: Oxitriptan (DB02959)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01653522
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02243150
Drug: G1T28-1 (CDK 4/6 Inhibitor)
Normalized name: Cyclin-dependent kinase (CDK) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02243150
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02474199
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-medication for darTregs infusion. A dose of 15 mg/kg will be administered 30 to 60 minutes prior to the darTregs infusion.
Study: NCT01026870
Drug: Placebo metered-dose inhaler BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 inhalations from a placebo metered-dose inhaler each morning and evening, approximately 12 hours apart, for 12 weeks.
Study: NCT04586803
Drug: SHR4640
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
Study: NCT01489046
Drug: Placebo matching with BMS-986001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, Oral, 0 mg, Once daily, At least 48 weeks
Study: NCT02135224
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02135224
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02619409
Drug: EPI25
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The EPI25 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.025cc, and sterile saline 0.075cc.
Study: NCT02619409
Drug: EPI50 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: The EPI50 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.05cc, and sterile saline 0.05cc
Study: NCT02619409
Drug: EPI75 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: The EPI75 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.075cc, and sterile saline 0.025%.
Study: NCT02619409
Drug: EPI100 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: The EPI100 group will receive bupivacaine 0.5% 3cc, and epinephrine 1:1000 0.1cc.
Study: NCT01714310
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiated at end of study week 4 and continued to study week 12.
Study: NCT01714310
Drug: fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initiated at end of study week 4 and continued to study week 12.
Study: NCT02822508
Drug: BLI801 Laxative
Normalized name: LAXATIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: BLI801 oral laxative
Study: NCT02822508
Drug: BLI801 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: BLI801 oral laxative placebo
Study: NCT00994448
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo tablet twice daily
Study: NCT03670810
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT01474642
Drug: Capecitabine/Cisplatin(XP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine/Cisplatin(XP) D1-D14 Capecitabine 2000mg/m2 D#2 PO D1 Cisplatin 75mg/m2 iv q 3 weeks
Study: NCT01474642
Drug: Capecitabine/Paditaxel(XG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine/Paditaxel(XG) D1-D14 Capecitabine 2000mg/m2 D#2 PO D1,D8 Paditaxel(genexol) 80mg/m2 iv q 3 weeks
Study: NCT01471548
Drug: TKI258
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04155515
Drug: TG-2349
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG-2349 400mg
Study: NCT04155515
Drug: DAG181
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAG181 200mg
Study: NCT00004903
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04156815
Drug: Oral isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral isotretinoin has remained the most effective medication for moderate-to-severe AV.Subjects received oral isotretinoin (Xingyi Yan'an Pharmaceutical, Shanghai, China) (1mg/kg/d for the first 2-4 weeks and 0.5mg/kg/d for the next 12-14 weeks) for a total of 16 weeks. Serum triglycerides, cholesterol and levels of liver enzymes were monitored every month during oral isotretinoin medication.
Study: NCT04339400
Drug: TQ05105
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQ05105 is a JAK2 inhibitor.
Study: NCT04183556
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: use of naproxen twice a day orally in mens time
Study: NCT02815748
Drug: SP2086
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP2086 was taken only one time at 100mg dose in health volunteers
Study: NCT02089061
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02153944
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was given orally during study visit
Study: NCT00807534
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo nebulization
Study: NCT00446719
Drug: Rellidep
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg P.O. daily for 8 weeks
Study: NCT01091571
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily during seven consecutive days
Study: NCT03077503
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 1 µg/kg diluted to 2 ml with 0.9% normal saline was administration. If adverse events were occurred, the patient will receive rescue drugs.
Study: NCT03077503
Drug: 0.9% normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline was use to dilute the study drugs
Study: NCT02340234
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to lebrikizumab will be administered as per the schedule specified in the respective arms.
Study: NCT04619056
Drug: CEB-01 membrane loaded with SN-38
Normalized name: sn-3-GPC
DrugBank: Choline alfoscerate (DB04660)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEB-01 is a polymeric drug with a delivery system loaded with SN-38, and will be placed in the surgical bed at the time of tumor resection.
Study: NCT00499603
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/m\^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
Study: NCT00499603
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg by mouth weekly on Days 1, 8, \& 15 for 12 cycles.
Study: NCT04036656
Drug: SYHA136 0.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT04036656
Drug: SYHA136 1 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT04036656
Drug: SYHA136 2.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT04036656
Drug: SYHA136 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT04036656
Drug: SYHA136 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT04036656
Drug: SYHA136 20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT04036656
Drug: SYHA136 35 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT04036656
Drug: SYHA136 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT04036656
Drug: Placebo matching SYHA136 0.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT04036656
Drug: Placebo matching SYHA136 1 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT04036656
Drug: Placebo matching SYHA136 2.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT04036656
Drug: Placebo matching SYHA136 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT04036656
Drug: Placebo matching SYHA136 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT04036656
Drug: Placebo matching SYHA136 20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT04036656
Drug: Placebo matching SYHA136 35 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT04036656
Drug: Placebo matching SYHA136 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT01639040
Drug: Placebo (for Dupilumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (for Dupilumab) once weekly (QW) for 4 weeks
Study: NCT03950518
Drug: Arginine hydrochloride
Normalized name: Arginine Hydrochloride
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AHC,12mg/d AH,40g/d
Study: NCT01274624
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-hour infusion of 400 mg/m2 on Day 1 every 2 weeks.
Study: NCT01274624
Drug: Fluorouracil (5-FU)
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m2 intravenous bolus followed by 2400 mg/m2 as a continuous intravenous infusion over 46 hours administered on Day 1 every 2 weeks.
Study: NCT01619033
Drug: BF2.649
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose 20 mg
Study: NCT01505127
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04464681
Drug: M201-A Injection
Normalized name: OCTINOXATE 2.45 g in 35 g / TITANIUM DIOXIDE 4.03 g in 35 g / ZINC OXIDE 1.72 g in 35 g / OCTISALATE 1.58 g in 35 g TOPICAL CREAM [15HR COVER LASTING M201 Medium Beige SPF50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Substance: M201-A Route of administration: continuous intravenous injection
Study: NCT04464681
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: M201-A Placebo Route of administration: continuous intravenous injection
Study: NCT01465646
Drug: levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01327352
Drug: Oshadi D
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT00400647
Drug: Enteric-coated Mycophenolate sodium (EC-MPS)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04209179
Drug: PCO371
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCO371 capsule
Study: NCT04209179
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule
Study: NCT02180334
Drug: Acetaminophen (paracetamol)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: On the day of MMTT, 3 tablets (1500 mg) of acetaminophen (paracetamol) will be administered orally to participants of both arms at the start of MMTT with manufactured mixed meal (0 min).
Study: NCT01554618
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01102413
Drug: Iron Sulphate
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral intake
Study: NCT01514695
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100mcg intravenously given in 2mL syringe at start of procedure
Study: NCT00477672
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, once daily by mouth, 6 weeks
Study: NCT01455012
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo. Subjects will be titrated to their optimal/maximal dose in weekly increments of 1 mg/24 h during a Titration Period. During Maintenance Period the subjects will continue on their optimal/maximal dose for 28 days. Following the Maintenance Period, subjects will be de-escalated over 7 days, depending on their optimal/maximal dose.
Study: NCT04657497
Drug: FOY-305
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified Dosage and Duration of Treatment
Study: NCT04657497
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified Dosage and Duration of Treatment
Study: NCT03041012
Drug: 3BNC117
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg 3BNC117 will be administered IV on day 7 and 21 after initiating ART
Study: NCT03041012
Drug: Antiretrovirals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination antiretroviral therapy
Study: NCT04074317
Drug: Regular Insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC injection
Study: NCT00373516
Drug: Vehicle (Placebo) applied BID
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00373516
Drug: QRX-101 75 mcg/g ointment applied QD
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00373516
Drug: QRX-101 75 mcg/g ointment applied BID
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00403273
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Intra-articular Injection of 5 cc of normal saline in the Painful TKA at screening visit
Study: NCT00160316
Drug: 0.5 Mg Estradiol and 2.5 Mg Dydrogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: p.o. daily
Study: NCT00610532
Drug: phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous phenytoin (15 mg/kg) single dose
Study: NCT00610532
Drug: phenytoin and probenecid
Normalized name: colchicine and probenecid
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous phenytoin (15 mg/kg) single dose and oral probenecid 2000 mg single dose
Study: NCT00849368
Drug: Azathioprine / Allopurinol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs are applied orally. A pre-specified dose escalation regimen will be chosen.~Azathioprine: Imurek (R) 50 mg and 25 mg tablets~Allopurinol: Mephanol (R) 100 mg tablets
Study: NCT04490434
Drug: DWP14012
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP14012 40mg, bid
Study: NCT04490434
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 200mg, bid
Study: NCT04490434
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen 500mg, bid